Atlas Trials

Study in Healthy Male Subjects to Demonstrate Bioequivalence of 1600 μg Selexipag Administered as Eight Tablets of 200 μg or as Single Tablet of 1600 μg

Clinical trial NCT02206295 · COMPLETED

Trial details

NCT number
NCT02206295
Sponsor
Actelion
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Bioequivalence
Start date
2012-09-01
Primary completion
2012-12-01
Enrollment
80

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.